🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

2. NovPod is a light-hearted informative intro to the specialty and an audio companion to the Novice Guide. Brought to you by creators and hosts Eoin Dore and Dr Duncan Kemp. bit.ly/43QpaFj

I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. Rasha Al-Lamee

Incredibly proud to celebrate Rasha Al-Lamee being awarded the Global CV Future Leader Award 2024 #GCVAwards. An exceptional mentor to us, who has also built a strong team of young researchers at Imperial College Matthew Shun-Shin Christopher Rajkumar Michael Foley Florentina Simader Shayna Chotai

Here we go again! Want to see if the coronary sinus reducer works in refractory angina? Watch Michael Foley present the results of the ORBITA-COSMIC in the main arena at #ACC this Monday #ORBITA Fiyyaz Ahmed-Jushuf Matthew Shun-Shin Shayna Chotai Christopher Rajkumar Florentina Simader

Amazing to see a brilliant friend and colleague Michael Foley present the #ORBITA-COSMIC trial of the coronary sinus reducer with simultaneous publication in The Lancet Rasha Al-Lamee NHLI Imperial NHS 💙 #ACC2024 thelancet.com/journals/lance…

Goodbye #ACC from the ORBITA team. Thank you for featuring our work and see you again next year! Florentina Simader Shayna Chotai Michael Foley Christopher Rajkumar Fiyyaz Ahmed-Jushuf Matthew Shun-Shin

How do you evaluate persistent symptoms after a #PCI procedure? At #EuroPCR, Dr. Christopher Rajkumar from #ORBITA demonstrates that when symptoms map to a stenosis, PCI is effective. Check out the full results in #JACC: bit.ly/4bfHcoJ Rasha Al-Lamee

#EuroPCR #JACC LBCT SimPub: #ORBITA-2 symptom-stratified analysis - Although symptom severity & nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of #PCI. bit.ly/3QK76cj Florentina Simader Rasha Al-Lamee

The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in JACC Journals by Florentina Simader and Christopher Rajkumar. PCI isn’t a therapy for all symptoms, it’s a therapy for angina Rasha Al-Lamee Matthew Shun-Shin

Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done Shayna Chotai on achieving the first of many big milestones during your PhD!

It was such a pleasure to join Rasha Al-Lamee to talk all things ESC 2024 Thank you so much The Lancet #chloewilson open.spotify.com/episode/5AeJOc…

#SimPub #CIrcTCT24 In the ORBITA-2 trial, severity of coronary stenosis (FFR/iFR) was predictive of anginal benefit in this placebo (sham procedure) controlled trial ahajrnls.org/3AnH9tS

Two new NovPods! Episode 8 Damien Hughes talks us through pain management in labour. Episode 9 Who knows most about obstetric anaesthetic drugs? Eoin Dore & Dr Rahul Bandopadhyay go head to head. 🎧 ow.ly/UfBl50TXbk3 #AnaesthesiaOnAir

From CAD to atherosclerotic coronary artery disease? The Lancet Commission led by Rasha Al-Lamee includes Davide Capodanno EuroIntervention Editor-in-Chief , MIЯVΛƬ #IC PCRonline Editorial Board member, Nieves Gonzalo #EuroPCR Course Director, and Nicole Karam, MD, PhD, FESC PCR Innovators Day

Our review discusses lessons learnt from ORBITA and ORBITA-2 and highlights the next key questions Rasha Al-Lamee Fiyyaz Ahmed-Jushuf Michael Foley sciencedirect.com/science/articl…